Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Patent Ductus Arteriosus Occlusion Device Oral Presentation #1 Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle 1/15/2003 Patent Ductus Arteriosus (PDA) Ductus arteriosus (DA) allows blood to bypass pulmonary and enter systemic Usually DA closes within 1018 hrs of delivery (if not deemed abnormal/patent) PDA occurs in 1/2500-5000 live births Many adverse effects (growth retardation, breathlessness or lack of appetite Most common problem is congestive heart failure 1/15/2003 Current Treatments Drug therapy (indomethacin) Implantable devices (most common are coils) Usually need 3-4 coils Difficult to remove and reposition Invasive surgery (ligate the PDA to inhibit blood flow) 1/15/2003 Project Goals To design, develop and patent a PDA occlusion device that can… Be delivered via a catheter Conform to the shape of the PDA and cause occlusion Can be repositioned Be cost effective (<$200) Provide an initial success rate of 100% 1/15/2003 Our Design 1/15/2003 Current Status Conducted extensive research on other treatment methods (to avoid short comings on our design) Design refinement finalization PDA Device prototype Design testing apparatus Making adjustments to website 1/15/2003 Needs Inquired with multiple companies about … Biocompatible and expandable foam Biocompatible memory wire Have not received a response and thus are seeking assistance from a biomaterials expert 1/15/2003 Future Direction Build a test device for the Patent Ductus environment Conduct strength and pressure testing Refine design based upon testing Build scaled prototype with correct biomaterials Talk with Dr. Doyle about patenting this PDA Occlusion Device 1/15/2003 Contact Information David Brogan Darci Phillips [email protected] 1-210-364-4546 [email protected] 1-615-386-9015 Daniel Schultz [email protected] 1-615-421-6067 1/15/2003